Monte Rosa Therapeutics
-
Roche Deal Aims to Get Molecular Glues to Stick to Elusive Cancer, Neuro Targets
Roche is paying $50 million up front to begin a drug R&D alliance with Monte Rosa Therapeutics, a biotech whose molecular glue technology could address targets previously deemed undruggable. It’s Roche’s second such deal in the past month.
-
With sickle cell disease study in sight, Graphite Bio draws up a $238M IPO
Gene-editing company Graphite Bio’s $238 million IPO was the biggest in biotech this week as it works toward human tests of a therapy that corrects the genetic mutation behind sickle cell disease. Elevation Oncology and Monte Rosa Therapeutics also made their stock market debuts, raising cash for clinical trials.
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.